Fabricating whole pine needles biomass with phenylhydrazine-4-sulphonic acid for effective removal of cationic dyes and heavy metal ions from wastewater.

We applied a holistic, sustainable, and green approach to develop an effective multipurpose adsorbent from whole pine needles (PNs), a forest waste lignocellulosic biomass. The PNs were oxidized and modified with phenylhydrazine-4-sulphonic acid (ɸHSO3H) to OPN-ɸHSO3H. The latter was characterized and tested as an adsorbent for cationic dyes, malachite green (MG), methylene blue (MB), crystal violet (CV), and metal ions (Hg2⁺ and Pb2⁺). The adsorption followed different kinetic models: Elovich for MG and MB, pseudo-second-order for CV, and pseudo-first-order for Hg2⁺ and Pb2⁺. Langmuir isotherm indicated maximum adsorption capacities of 303.4 ± 8.91 mgg-1 (MG), 331.4 ± 17.50 mgg-1 (MB), 376.6 ± 22.47 mgg-1 (CV), 210.8 ± 28.86 mgg-1 (Hg2⁺), and 172.9 ± 20.93 mgg-1 (Pb2⁺) within 30 min. Maximum removal efficiencies were 99.0% (MG), 98.0% (MB), 96.04% (CV), 95.5% (Hg2⁺), and 89.8% (Pb2⁺). The adsorbent demonstrated significant regeneration and reusability over ten cycles, proving highly efficient for both cationic dyes and metal ions, with wide potential for practical applications where more than one adsorbate is present.

Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.

BACKGROUND: dyslipidemia is common and is often treated with 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins). Little is known about the comparative effectiveness of statins among human immunodeficiency virus (HIV)-infected patients. This study compared the effectiveness and toxicity of statins among HIV-infected patients in clinical care. METHODS: we conducted a retrospective cohort study of patients starting their initial statin medications at 2 large HIV clinics (N = 700). The primary observation was change in lipid levels during statin therapy. Secondary observations included whether individualized National Cholesterol Education Program (NCEP) goals for low density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) levels were reached, and toxicity rates. We used linear regression to examine change in lipid levels, controlling for baseline lipid values and demographic and clinical characteristics. We conducted secondary analyses using propensity scores to address confounding by indication. RESULTS: the most commonly prescribed statins were atorvastatin (N = 303), pravastatin (N = 280), and rosuvastatin (N = 95). One year after starting a statin therapy, patients who received atorvastatin or rosuvastatin had significantly greater decreases in total cholesterol, LDL-C, and non-HDL-C than patients on pravastatin. The likelihood of reaching NCEP goals for LDL-C levels was higher with the use of rosuvastatin (OR 2.1; P = .03) and atorvastatin (odds ratio [OR], 2.1; P = .001) compared with that of pravastatin. The likelihood of reaching NCEP goals for non-HDL-C levels was higher for rosuvastatin (OR 2.3; P = .045) but not atorvastatin (OR, 1.5; P = .1) compared with pravastatin. Toxicity rates were similar for all 3 statins: 7.3% for atorvastatin, 6.1% for pravastatin, and 5.3% for rosuvastatin. CONCLUSIONS: our findings suggest that atorvastatin and rosuvastatin are preferable to pravastatin for treatment of HIV-infected patients with dyslipidemia, due to greater declines in total cholesterol, LDL-C, and non-HDL-C, with similar lower toxicity rates.